Glypican-based drug releasing titania implants to regulate BMP2 bioactivity as a potential approach for craniosynostosis therapy

Titania nanotube- based protein delivery implants have been assessed in vitro to provide a sustained release of bone inhibiting glypicans (rGPC1 and rGPC3). The bioactivity of released glypicans was confirmed by downregulation of BMP2 expression in transfected C2C12 cells.215